Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

LENSAR, Inc. LNSR

Healthcare — Medical Devices

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership
19.98%

Capital & Financial Ratios

Market Cap
87.11
Revenue
60.26
Net Income
34.70
Free Cash Flow
(7.40)
Net Debt
(13.56)
Current Ratio
2.39
Debt/Equity
0.00
P/E ratio
5.58
P/S ratio
1.45
P/B ratio
5.85
Past 5Y EPS Growth
(14.63%)
This Y EPS Growth
102.29%
Next Y EPS Growth
(3.20%)
Next 5Y EPS Growth
—
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 24.06 22.46 17.98 13.57
Receivables 4.00 6.09 6.38 6.17
Inventory 15.69 11.43 21.52 24.87
Other — — — —
46.44 41.98 46.77 47.03
2023 2024 2025 Q'26
Payables 4.01 6.00 18.98 11.19
ST’ Debt — — — —
Other — — 10.00 —
11.63 15.00 40.57 19.64
in millions of $

Compound Annual Growth

10y 5y 3y
Sales — ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow — ‡‡‡ ‡‡‡
Earnings — ‡‡‡ ‡‡‡
Book Value — ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 13.43 16.50 — —
—
’25 14.16 13.94 14.32 16.03
58.44
’24 10.59 12.64 13.54 16.73
53.49
’23 8.25 12.01 9.80 12.11
42.16
’22 9.34 8.04 7.75 10.23
35.36
’21 7.04 7.92 8.27 11.22
34.46
’20 5.91 5.05 7.15 8.28
26.38
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (4.27) (0.13) — —
—
’25 (6.94) (5.00) (3.51) 0.62
(14.83)
’24 (5.31) (3.78) 3.15 3.66
(2.27)
’23 (6.70) (2.14) (0.34) (0.48)
(9.66)
’22 (2.61) (2.79) (4.70) (4.76)
(14.86)
’21 (4.62) (1.46) (2.15) (0.74)
(8.97)
’20 (6.36) (5.37) (0.05) (2.00)
(13.79)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (4.27) (0.16) — —
—
’25 (6.94) (5.07) (3.51) 0.62
(14.91)
’24 (5.33) (3.89) 3.13 3.65
(2.43)
’23 (6.70) (2.32) (0.34) (0.52)
(9.89)
’22 (2.65) (2.80) (4.70) (4.81)
(14.97)
’21 (4.73) (1.48) (2.21) (0.89)
(9.32)
’20 (6.46) (5.52) (0.04) (2.10)
(14.12)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.00 0.10 — —
—
’25 (2.32) (0.15) (0.31) (0.12)
(2.87)
’24 (0.19) (0.79) (0.13) (1.61)
(2.73)
’23 (0.40) (0.81) (0.23) (0.35)
(1.31)
’22 (0.67) (0.67) (0.39) (0.24)
(1.96)
’21 (0.56) (0.47) (0.65) (0.41)
(2.09)
’20 (0.34) — (0.64) (0.78)
(4.28)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
— — — — ‡‡‡‡ ‡‡‡‡ 2.15 1.80 2.67 7.25 — — —
Low Price
— — — — ‡‡‡‡‡ ‡‡‡‡ 8.80 4.49 9.23 17.31 — — —
High Price
— — — ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 110 130 140 150 — — —
Employees
— — ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.32 0.32 0.38 0.39 — — —
Revenue/Emp
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 35.36 42.16 53.49 58.44 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 56.44% 50.06% 48.33% 46.41% — — —
Gross Margin
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.91) (14.38) (31.40) (34.28) ‡‡‡‡‡ — —
EBT
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (56.32%) (34.11%) (58.71%) (58.66%) ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
— ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (19.91) (14.38) (31.40) (34.28) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.41 3.50 3.68 4.32 — — —
Depreciation
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.48 3.84 4.64 4.89 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.96) (1.31) (2.73) (2.87) ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
Earnings/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.46) (0.88) (0.20) (1.24) — — —
Cash Flow/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) (0.02) (0.01) (0.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.47) (0.90) (0.21) (1.25) — — —
Free CF/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.13 3.05 0.42 (2.18) — — —
Book Value/Sh
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 10.16 10.97 11.52 11.96 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
— — ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡
PE Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.78 1.05 1.92 2.38 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.66 1.33 21.18 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.45 0.54 1.55 2.11 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.06) (2.29) (34.13) (8.28) — — —
EV/FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (14.86) (9.66) (2.27) (14.83) ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.11) (0.24) (0.16) (0.08) — — —
Capex
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (14.97) (9.89) (2.43) (14.91) — — —
FCF
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 22.30 34.81 26.98 6.20 — — —
Working Cap'
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.80 — — — — — —
Total Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (11.87) (24.06) (22.45) (17.98) — — —
Net Debt
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 41.98 33.43 4.86 (26.02) — — —
Sh' Equity
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (32.56%) (22.93%) (46.22%) (49.78%) ‡‡‡‡‡ — —
ROA
— — ‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (41.88%) (81.61%) 0.00% 0.00% — — —
ROIC
— — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (41.12%) (38.14%) (164.03%) 324.05% ‡‡‡‡‡ — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

LENSAR, Inc. (LNSR), a medtech innovator in cataract laser systems, boasts impressive revenue growth from $24.4 million in 2018 to $53.5 million in 2024 (22% CAGR), fueled by its ALLY system and rising consumables revenue, with analysts forecasting a tripling to $111 million by 2027. Employee productivity is improving, signaling scalable operations, but gross margins have slipped to 48.3%, and the company remains deep in the red with widening net losses (-$31.4 million in 2024) and negative free cash flow.

The balance sheet tells a cautionary tale: shareholders’ equity has plummeted 93% to $4.9 million, book value per share crashed 86%, and share dilution has surged 150% since 2020 amid ongoing cash burn. Trading at a premium to consensus targets with sky-high multiples (PS 1.92, PB 21.2), the stock looks frothy, lacking insider buying and vulnerable to correction if growth falters.

While forecasts eye breakeven and positive EPS by 2027 via international expansion and consumables ramp-up, risks like margin erosion, competition from giants, and further dilution loom large. This analysis weighs the high-upside potential against prudent red flags—perfect for risk-tolerant investors eyeing medtech tailwinds.

Read full commentary →

LENSAR, Inc. (LNSR) Latest News

News by impact score

Fine-tune

20 Aug

4 transcript www.fool.com, 10:13 AM
LENSAR (LNSR) held its Q2 2026 earnings call, presenting financial results, operational updates, and forward outlook for the company. Earnings call delivers core quarterly results and guidance that typically drive immediate valuation shifts and investor positioning.

13 Aug

4 , 7:07 PM
LENSAR Inc posted record revenue and a sharp profitability increase in Q2 2026. Record revenue and profitability gains signal major financial momentum that can lift stock valuation and growth outlook.

3 www.marketbeat.com, 1:04 PM
LENSAR Inc. reported Q2 financial results and operational updates during its earnings call, including revenue figures, product developments, and forward-looking guidance. Q2 earnings details and outlook can shift near-term investor sentiment and valuation but rarely alter long-term company trajectory.

3 transcript app.moby.co, 1:00 PM
LENSAR, Inc. held its Q2 2026 earnings call covering quarterly financial results, operational updates, and forward outlook for the company's laser cataract surgery systems and related products. Quarterly earnings calls deliver financial and strategic updates that typically produce moderate short-term effects on valuation and sentiment.

4 Jun

4 Simply Wall St., 4:14 PM
LENSAR's failed deal triggers a new $10 price target and shifts the company's outlook. Failed deal plus new price target point to major valuation and strategic changes.

1 Jun

3 transcript www.fool.com, 1:10 PM
Lensar Inc. released its Q1 2026 earnings results and held an earnings call discussing financial performance, operations, and outlook. Quarterly earnings transcript supplies updated financials and guidance that can moderately shift near-term investor sentiment and valuation.

3 transcript www.fool.com, 1:10 PM
Lensar (LNSR) held its Q4 2025 earnings call, covering quarterly financial results, operational updates, and forward outlook. Quarterly earnings data typically moves near-term sentiment and valuation without altering long-term strategy.

8 May

4 www.marketbeat.com, 2:20 PM
LENSAR, Inc. (LNSR) released Q1 earnings call highlights, covering financial results, operational updates, and forward guidance. Q1 earnings call highlights reveal financial performance and strategic outlook, significantly impacting stock trajectory and investor sentiment.

4 GlobeNewswire, 7:00 AM
LENSAR, Inc. reported a 34% revenue increase in Q1 2025, totaling $14.2 million, driven by a 33% rise in worldwide procedure volumes and the placement of 14 ALLY Robotic Laser Cataract Systems. The company has a backlog of 24 systems pending installation. Despite the revenue growth, LENSAR experienced a net loss of $27.3 million, attributed to increased expenses related to a proposed merger with Alcon Research. The installed base of ALLY Systems reached approximately 150, contributing to the overall growth. Cash and investments rose to $25.2 million, aided by a $10 million deposit from the Alcon transaction. The proposed merger with Alcon and significant revenue growth are likely to significantly impact LENSAR's future performance and market position.

3 GlobeNewswire, 7:00 AM
LENSAR, Inc. reported first quarter 2026 financial results and provided a business update. Quarterly earnings and business updates moderately affect financial performance and market sentiment.

21 Apr

4 , 1:03 AM
Failed Alcon deal reframes LENSAR (LNSR) story positively, highlighting $10 upside potential. Failed Alcon deal shifts investor narrative toward LENSAR's undervalued growth prospects with $10 target.

4 Apr

4 Simply Wall St., 8:18 PM
LENSAR (LNSR) story shifts post-failed Alcon deal, with analysts resetting price targets amid ongoing commercialization challenges, ALLY system adaptations, and uncertain growth path. Failed Alcon acquisition and lowered price targets represent major strategic setbacks altering LNSR's trajectory and investor sentiment.

3 Apr

4 GuruFocus.com, 9:00 PM
LENSAR Inc (LNSR) Q4 2025 earnings call highlights growth amid operational and market challenges, with focus on strategic navigation for future performance. Q4 earnings highlights detail growth strategies offsetting challenges, poised to significantly sway investor sentiment and company trajectory.

1 Apr

4 app.moby.co, 8:30 AM
LENSAR, Inc. released Q4 2025 earnings call summary highlighting financial results, revenue growth, procedural volumes, and outlook for ALLY Adaptive Cataract Treatment System. Q4 earnings summary details revenue beats, system adoptions, and guidance that significantly shape LNSR's financial trajectory and stock performance.

31 Mar

4 GlobeNewswire, 6:00 AM
LENSAR, Inc. (LNSR) reported fourth quarter and full year 2025 financial results and provided a business update. Q4 and full-year results plus business update represent major financial disclosures and strategic insights likely to alter investor sentiment and company trajectory.

3 www.marketbeat.com, 10:10 AM
LENSAR reported Q4 revenue up 16% to $11.4 million, driven by ALLY System adoption and 14% procedure growth; full-year revenue hit $40.3 million; 2024 guidance projects $46-48 million revenue with gross margins improving to 58-60%; announced leadership changes and cost-saving measures. Q4 results show solid growth and positive guidance influencing financial performance moderately amid competitive medtech landscape.

17 Mar

4 www.medtechdive.com, 6:57 AM
Alcon has abandoned its effort to purchase LENSAR, Inc. (LNSR) after facing scrutiny from the FTC. Abandonment of a potential acquisition by Alcon due to FTC scrutiny significantly disrupts LNSR's strategic trajectory and market valuation.

16 Mar

4 Business Wire, 4:57 PM
Alcon and LENSAR, Inc. (LNSR) mutually agreed to terminate their merger agreement, with both parties citing recent changes in market conditions. Merger termination eliminates acquisition premium for LNSR shareholders and forces standalone operations amid uncertain market dynamics.

4 GlobeNewswire, 4:30 PM
LENSAR, Inc. (LNSR) announced the termination of its merger agreement with Alcon Research, LLC. Termination of a major merger agreement disrupts LNSR's strategic growth plans and likely triggers negative market reaction.

25 Feb

5 GlobeNewswire, 5:00 PM
LENSAR provides update on pending acquisition by Alcon. Pending acquisition by Alcon fundamentally redefines LENSAR's ownership, operations, and long-term prospects.

6 Nov

4 , 7:00 AM
LENSAR, Inc. (LNSR) reported its financial results for the third quarter of 2025, highlighting significant growth in revenue and an increase in product demand. The company provided updates on its strategic initiatives, including advancements in its laser cataract surgery technology and expansion into new markets. Management expressed optimism about future performance, citing strong customer feedback and ongoing investments in innovation. Overall, the results indicate a positive trajectory for LENSAR as it continues to enhance its competitive position in the ophthalmic surgical market. Significant growth in revenue and advancements in technology indicate a strong potential for future performance.

7 Aug

4 GlobeNewswire, 7:00 AM
LENSAR, Inc. (LNSR) reported its financial results for the second quarter of 2025, highlighting a significant increase in revenue and improved operational efficiency. The company also provided updates on its product pipeline and strategic initiatives aimed at enhancing market presence. Management expressed optimism about future growth prospects and outlined plans for upcoming product launches and market expansion efforts. The reported revenue growth and strategic initiatives indicate a significant impact on future performance and market positioning.

24 Mar

4 , 8:00 AM
Alcon has reached an agreement to acquire LENSAR, Inc. (LNSR), a company specializing in advanced cataract surgery technology. This acquisition aims to enhance Alcon's portfolio in the ophthalmic surgical space, leveraging LENSAR's innovative solutions to improve patient outcomes. The deal is expected to close in the coming months, pending regulatory approvals. The acquisition by Alcon is a significant strategic move that could enhance LENSAR's market position and growth potential in the ophthalmic sector.

28 Feb

4 , 2:17 AM
LENSAR, Inc. (LNSR) reported record revenue growth in Q4 2024, driven by strategic market initiatives and increased demand for its innovative ophthalmic technologies. The company highlighted significant advancements in its product offerings and a robust pipeline aimed at enhancing its competitive position in the eye care sector. Management expressed optimism about future growth prospects and ongoing investments in research and development to sustain momentum. Record revenue growth and strategic initiatives are likely to significantly impact LENSAR's future performance and market positioning.

27 Feb

4 GlobeNewswire, 7:00 AM
LENSAR, Inc. reported strong financial results for Q4 and full year 2024, with a 38% increase in quarterly revenue and a 27% rise in annual revenue. The company placed 31 ALLY Robotic Cataract Laser Systems in Q4, totaling over 80 for the year, and achieved a recurring revenue exceeding $40 million. Despite a GAAP net loss of $18.7 million in Q4, LENSAR experienced positive Adjusted EBITDA for the second consecutive quarter. The company anticipates continued revenue growth in 2025, driven by strong demand for ALLY Systems and new regulatory clearances in the EU and Taiwan. Significant growth in system placements and recurring revenue, along with positive Adjusted EBITDA, indicates a strong trajectory for LENSAR's future performance.

25 Jan

3 Simply Wall St., 7:15 AM
LENSAR, Inc. (NASDAQ:LNSR) experienced a 13% surge in its stock price, benefiting both retail investors, who hold 40% of the shares, and institutional investors. This increase reflects positive market sentiment towards the company. The stock surge indicates a moderately noticeable influence on market sentiment and potential financial performance.

20 Dec

4 , 5:46 AM
LENSAR, Inc. aims for profitability in the future. The potential impact of achieving profitability on LENSAR, Inc.'s future and market performance is significant.

9 Nov

4 , 8:35 AM
LENSAR, Inc. (LNSR) beats expectations in third quarter 2024 earnings. The earnings beat is a significant event that could alter the company's trajectory and investor sentiment.

8 Nov

4 , 2:14 AM
LENSAR Inc (LNSR) reported record revenue growth and strategic expansion in Q3 2024. The significant revenue growth and strategic expansion are expected to have a major impact on LENSAR, Inc.'s future trajectory and investor sentiment.

7 Nov

3 , 7:00 AM
LENSAR reports third quarter 2024 results and provides business update. The news of the third quarter results and business update may moderately influence key areas such as financial performance and competitive positioning.
© 2016–2026 stockrow.com Terms and Conditions Indicators Contact Us